Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?

The decision to administer adjuvant chemotherapy in treatment of early invasive breast cancer (EBC) is often complex, particularly for hormone receptor-positive (HR+) diseases, and current guidelines often classify these patients in an intermediate-risk group. Several biomarkers are currently availa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Manag Res
Autores principales: Alexandre, Marie, Maran-Gonzalez, Aurélie, Viala, Marie, Firmin, Nelly, D’Hondt, Véronique, Gutowski, Marian, Bourgier, Céline, Jacot, William, Guiu, Séverine
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912012/
https://ncbi.nlm.nih.gov/pubmed/31849525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S221676
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares